Amsterdam Molecular first half 2010 net loss in line with last year

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today reported its results for the first half year of 2010.

Highlights - Glybera(R): - EMA initiated MAA review in 01/2010 - Approval progressing on schedule for decision mid 2011 - Novel biomarker for Glybera(R) activity identified - Hemophilia B: Phase I/II started - Duchenne Muscular Dystrophy: to benefit from EUR 4 million innovation credit - sRNA: silencing gene therapy technology achieves 80% cholesterol reduction - Supervisory Board nominations: 3 new industry professionals slated to join board - Key financial figures in line with guidance - Cash & cash equivalents of EUR 13.5 million at June 30, 2010

"We are very pleased with the key milestones we have achieved in the first half year of 2010 in the Glybera(R) approval process which seems firmly on track. Our dialogue with the EMA is very encouraging and we look forward to the Agency's decision with confidence. We also continue to make progress with our pipeline, not only on the partnership front for programs such as Hemophilia B, but also in our early stage efforts," said Jorn Aldag, chief executive officer of AMT.

Operations

Glybera(R) for Lipoprotein Lipase Deficiency (LPLD)

In January 2010, the European Medicines Agency (EMA) commenced review of AMT's Marketing Authorization Application. In May 2010 AMT received questions (Day 120 questions) regarding the application. In July we met with the EMA, to clarify the questions they raised, enabling AMT to align its response strategy. We are now working towards an official response to the EMA Day 120 questions, due by the end of 2010.

As of today we remain confident in the approvability of Glybera(R). Our assessment is based on the following:

- Our response to the EMA does not require further clinical trials with additional new to be treated patients. We expect to be able to formulate our response satisfactorily by submitting data and further analyses from already treated patients. - More, highly relevant, data from our last clinical trial CT-AMT-011-02 AMT strongly suggest that Glybera's effects are lasting (one year) via a mechanism that causes clearance of chylomicrons, the fat carrying particles which are responsible for pancreatitis in LPLD patients. - Overall we have developed a clear response strategy, which, if executed with no unforeseen adverse events or delays, should allow us to remain on track for a positive EMA decision in the middle of 2011.

Hemophilia B

Further to their 2009 agreement to co-develop a vector-gene combination for the treatment of Hemophilia B, AMT and St. Jude Children's Research Hospital in the USA have successfully transferred Factor IX to AMT's manufacturing platform and have demonstrated proof of concept in animals in 2010. The multicenter, dose escalation study with this vector-gene combination began in March, 2010 at University College London Hospital in the United Kingdom guided by Prof. Amit Nathwani. The first patient has been dosed successfully and demonstrated good results both in terms of clinical benefit and side effects. Further enrolment of patients is expected in the second half of 2010.

Duchenne Muscular Dystrophy

In support of its program to treat Duchenne Muscular Dystrophy, AMT received an investment credit from SenterNovem (now Agentschap.nl), the Dutch government innovation agency, in January 2010. The credit comprises a loan covering 35% of the costs of the project through to 2013 with a maximum of EUR 4 million. The loan is repayable only if AMT successfully commercializes the program. AMT has shown proof of concept in a pre-clinical model with its optimized construct for exon skipping using its proprietary AAV technology.

Parkinson's Disease

Together with the University of Lund, Sweden, AMT is diligently working on the preclinical development of a gene therapy for delivery of the GDNF gene to the brain. Efficacy data in an animal model of PD is anticipated to be available by the end of the current year

sRNA

Elevated levels of cholesterol are a major risk factor and contributor to the development of atherosclerosis and cardiovascular disease (CVD). Early research at AMT demonstrates that after a single intravenous injection of a silencing gene therapy in animal models, the serum cholesterol levels were reduced by 80% with no signs of toxicity. It is therefore reasonable to expect a similar effect in patients, resulting in reduced risk for atherosclerosis or CVD. Such a long-term, perhaps life-long active gene therapy could eliminate the need for maintenance statin therapy.

Supervisory Board changes

During the period ended June 30, 2010, Alexander Ribbink and George Morstyn retired from the Supervisory Board and AMT thanks them for their substantial contributions. On April 28, 2010, AMT's co-founder Sander van Deventer was appointed to the Supervisory Board, and in addition Joseph M. Feczko, Steven H. Holtzman and Francois Meyer were nominated to the Supervisory Board for consideration at the Extraordinary General Meeting to be held on September 20, 2010.

Financials

Results comparison

Total net loss for the period ended June 30, 2010 amounted to EUR 9.4 million, in line with the net loss for the period ended June 30, 2009 which also amounted to EUR 9.4 million.

The main item within operating costs reflects the investment in Glybera(R) to support the registration process. Development of our Duchenne Muscular Dystrophy program, which is 35% funded by a research credit from SenterNovem through to completion of a Phase I clinical study continues. Expenditure on our other development projects has been reduced as we are constrained by our current resources and are focusing on the successful completion of the Glybera registration process. Research and development costs increased to EUR 8.1 million for the period ended June 30, 2010 from EUR 7.1 million in the same period of 2009. At the same time, general and administrative costs decreased to EUR 1.8 million in the period ended June 30, 2010 from EUR 2.9 million in the same period of 2009.

Net interest income/(cost) decreased to EUR (0.0) million for the period ended June 30, 2010 from EUR 0.5 million in the same period in 2009 as a result of the Company's decreasing cash balance combined with continuing low market interest rates for deposits.

Cash and cash equivalents amounted to EUR 13.5 million at June 30, 2010, a decrease of EUR 9.1 million compared to EUR 22.6 million at December 31, 2009. The decrease in cash and cash equivalents mainly stems from the operational cash outflow which amounted to EUR 8.9 million for the period ended June 30, 2010 (compared to an operating cash outflow of EUR 9.5 million for the period ended June 30, 2009).